Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cognition study of dimethyl fumarate in relapsing-remitting multiple sclerosis
2013-001422-25Phase 3Completed
- Sponsor
- Biogen
- Start
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of dimethyl fumarate in relapsing-remitting multiple sclerosis (RRMS), sponsored by Biogen. Primary endpoint: Proportion of patients with worsening in cognitive impairment. Started Apr 2013; status: completed.
02
Drugs
dimethyl fumarate
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2013-001422-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001422-25.